Who is sponsoring NCT05673655?

NCT05673655 is sponsored by Fayoum University.

What drugs are being tested in NCT05673655?

Interventions in NCT05673655: intraoral trigger point injection by botox, transcutaneous trigger point injection by botox.

What condition does NCT05673655 study?

NCT05673655 studies Myofacial Pain.

Is NCT05673655 still recruiting?

NCT05673655 is currently status unknown. Last updated 10 January 2023.

Last reviewed 2023-01-10 · How we verify

NCT05673655

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intraoral Injection of Trigger Points by Botox

Status unknown Phase 2 Last updated 10 January 2023

What this trial tests

Phase 2 trial testing intraoral trigger point injection by botox in Myofacial Pain in 40 participants. Status unknown.

Timeline

25 December 2022

Primary endpoint
1 February 2023

25 February 2023

Quick facts

Lead sponsor	Fayoum University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	40
Start date	25 December 2022
Primary completion	1 February 2023
Estimated completion	25 February 2023
Sites	1 location across Egypt

Drugs / interventions tested

intraoral trigger point injection by botox — full drug profile →
transcutaneous trigger point injection by botox — full drug profile →

Conditions studied

Myofacial Pain — all drugs for Myofacial Pain →

Sponsor

Fayoum University

Who can join

Adults 18 to 60, any sex, with Myofacial Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with orofacial pain lasting at least 3 months. The patients will be randomly assigned to one of the two groups according to the treatment method: group I (intraoral injection) and group II (transcutaneous injection) where each patient injected Botox at each trigger point according to the treatment group by the same operator. Patients will be examined by a blinded investigator at pre- and post-injections at the following intervals: during diagnosis, 1 week, 4, and 6 weeks post-injection. The patients will be assessed using a pain score measured on a 10-point visual analog scale (VAS). The secondary outcome assessed will be measuring the quality of life in an Oral Health Impact Profile questionnaire (OHIP-14).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effectiveness of intra-oral botulinum toxin injection in comparison to the extra-oral approach on pain and quality of life in patients with myofascial pain: a randomized clinical trial.
Shabaan AA, Kassem I, Aboulmagd I, Amer IA, et al · · 2024 · cited 1× · PMID 39681752 · DOI 10.1007/s00784-024-06051-0

Verify or expand the search:

Other recruiting trials for Myofacial Pain

Currently open trials in the same condition.

NCT07133139 — Treatment Validation for Myofascial Pain · NA · recruiting
NCT06869161 — Comparison of Treatment Alternatives for Myofascial Pain Causing Central Sensitization · NA · active not recruiting
NCT04640896 — Trigger Point Injections in Anterior Cervical Surgery · Phase 4 · recruiting

Other Fayoum University trials

Trials by the same sponsor.

NCT07536620 — Metformin and Alveolar Cleft · Phase 2 · not yet recruiting
NCT07444970 — Comparative Evaluation of Xenograft Alone and Sticky Bone in Sinus Lift With Concurrent Implant Placement · NA · not yet recruiting
NCT07394179 — Transforming Channel Osteotomy Into Tunnel Osteotomy in Zygomatic Implant Preparation · NA · not yet recruiting
NCT07277348 — Analysis of The Outcomes of Therapeutic Photorefractive Keratectomy Combined With Prophylactic Accelerated Cross-Linking · NA · not yet recruiting
NCT07330726 — Lidocaine Patch and Lower Third Molar · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05673655 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fayoum University
Last refreshed: 10 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05673655.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing